Zentalis Pharmaceuticals (ZNTL) EBT (2022 - 2025)
Historic EBT for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$26.7 million.
- Zentalis Pharmaceuticals' EBT rose 3357.97% to -$26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.5 million, marking a year-over-year increase of 1650.93%. This contributed to the annual value of -$165.7 million for FY2024, which is 4016.08% up from last year.
- Per Zentalis Pharmaceuticals' latest filing, its EBT stood at -$26.7 million for Q3 2025, which was up 3357.97% from -$26.9 million recorded in Q2 2025.
- Zentalis Pharmaceuticals' EBT's 5-year high stood at $10.2 million during Q1 2024, with a 5-year trough of -$99.5 million in Q2 2023.
- Moreover, its 4-year median value for EBT was -$52.3 million (2022), whereas its average is -$51.0 million.
- As far as peak fluctuations go, Zentalis Pharmaceuticals' EBT skyrocketed by 11673.62% in 2024, and later crashed by 57411.37% in 2025.
- Zentalis Pharmaceuticals' EBT (Quarter) stood at -$48.5 million in 2022, then decreased by 25.87% to -$61.1 million in 2023, then grew by 21.94% to -$47.7 million in 2024, then soared by 44.02% to -$26.7 million in 2025.
- Its EBT was -$26.7 million in Q3 2025, compared to -$26.9 million in Q2 2025 and -$48.3 million in Q1 2025.